Ultragenyx Pharmaceutical Inc.

Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference

Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update

Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy